Skip to main content
John Moran, MD, Cardiology, Maywood, IL

JohnFMoranMD

Cardiology • Maywood, IL

Adult Congenital Heart Disease

Professor of Medicine, Loyola University-Stritch School of Medicine

Join to view full profile

Dr. Moran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Moran's full profile

Already have an account?

  • Office

    Loyola University Medical Center
    (Luh - North Ent., Rm7604)
    Maywood, IL 60153
    Phone+1 708-216-8757
    Fax+1 708-216-1259

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Cardiovascular Disease, 1967 - 1969
  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1965 - 1967
  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoInternship, Internal Medicine, 1964 - 1965
  • Loyola University Chicago Stritch School of Medicine
    Loyola University Chicago Stritch School of MedicineClass of 1964

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1966 - 2017

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
  • Super Doctor SuperDoctors.com
  • Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

Press Mentions

  • ProMetic Life Sciences Inc. (PFSCF: OTCQX International) | US FDA Grants Orphan Drug Designation to Prometic’s PBI-4050 Drug for the Treatment of Alström Syndrome
    ProMetic Life Sciences Inc. (PFSCF: OTCQX International) | US FDA Grants Orphan Drug Designation to Prometic’s PBI-4050 Drug for the Treatment of Alström SyndromeMarch 3rd, 2017
  • ProMetic’s PBI-4050 Receives Promising Innovative Medicine Designation from the UK MHRA for the Treatment of Alström Syndrome
    ProMetic’s PBI-4050 Receives Promising Innovative Medicine Designation from the UK MHRA for the Treatment of Alström SyndromeJanuary 24th, 2017
  • European Commission Grants ProMetic’s PBI-4050 Orphan Drug Status for Alström Syndrome
    European Commission Grants ProMetic’s PBI-4050 Orphan Drug Status for Alström SyndromeJanuary 20th, 2017
  • Join now to see all

Professional Memberships

Dr. John Moran, Dr. John Moran, MD, Dr. J Moran, Dr. John F Moran